Cardinal Health Raises Full-Year Guidance After Q3 Earnings Beat

According to reports, Cardinal Health reported fiscal Q3 2026 earnings per share that exceeded analyst consensus estimates. Following this strong performance, the company raised its full-year EPS guidance. The stock price also managed to climb above its 200-day moving average, despite experiencing recent weakness relative to its healthcare sector peers.

This outperformance comes as the pharmaceutical distribution sector faces mixed pressures, with market data showing relative margin stability despite pricing volatility. Compared to competitors such as McKesson and Cencora, Cardinal Health maintained a steady growth pace, with market experts noting that the guidance raise reflects operational efficiency in both the pharmaceutical and medical segments. These results have bolstered investor confidence following a period of lagging performance relative to the broader healthcare index.

In terms of trading, Cardinal Health shares settled at significant technical levels after clearing their long-term average (close May 15, 2026). Looking at the economic calendar, investors are monitoring upcoming US Consumer Price Index (CPI) data, which could influence market sentiment toward value and growth stocks within the healthcare sector. Support levels near the 200-day moving average will remain a key watch point for traders in upcoming sessions.